Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Parenthetical) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended				6 Months Ended
	Jun. 29, 2014		Jun. 30, 2013		Jun. 29, 2014 Employee		Jun. 30, 2013
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected number of positions eliminated					300
Restructuring charges	$ 66	[1]	$ 150	[1]	$ 106	[1]	$ 245	[1]
Global Innovative Pharmaceutical [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	9				11
Global Established Pharmaceutical [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	24				31
Global Vaccines, Oncology and Consumer Healthcare [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	6				6
Worldwide Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	8		12		9		15
Manufacturing Operations [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	12		80		38		82
Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7		4		11		81
Commercial operations [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 54				$ 67

[1] In the six months ended June 29, 2014, Employee terminations represent the expected reduction of the workforce by approximately 300 employees, mainly in manufacturing and sales.The restructuring charges in 2014 are associated with the following:•For the three months ended June 29, 2014, the Global Innovative Pharmaceutical segment (GIP) ($9 million), the Global Established Pharmaceutical segment (GEP) ($24 million), the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($6 million), Worldwide Research and Development and Medical ($8 million), manufacturing operations ($12 million) and Corporate ($7 million).•For the six months ended June 29, 2014, the Global Innovative Pharmaceutical segment (GIP) ($11 million), the Global Established Pharmaceutical segment (GEP) ($31 million), the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($6 million), Worldwide Research and Development and Medical ($9 million), manufacturing operations ($38 million) and Corporate ($11 million).The restructuring charges in 2013 are associated with the following:•For the three months ended June 30, 2013, total operating segments ($54 million), Worldwide Research and Development and Medical ($12 million), manufacturing operations ($80 million) and Corporate ($4 million). •For the six months ended June 30, 2013, total operating segments ($67 million), Worldwide Research and Development and Medical ($15 million), manufacturing operations ($82 million) and Corporate ($81 million).At the beginning of fiscal 2014, we revised our operating segments and are unable to identify these prior-period restructuring charges to the new individual segments.